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Significance Statement 
This study reports that publically available gene array expression data together with 
statistically significant connections’ map (sscMap) can successfully predict already licensed 
drugs to modify genes of interest. We applied this bioinformatics approach to the NF-κB 
regulator A20 (TNFAIP3), which is reduced in Cystic Fibrosis (CF) airway cells. sscMap 
predicted drugs that should or are predicted to induce A20 and normalise the inflammatory 
response in CF airways. Using airway epithelial cells we show that ikarugamycin and 
quercetin have anti-inflammatory effects mediated by induction of A20 in CF and non-CF 
airway epithelial cells. Using siRNA techniques we confirm that the anti-inflammatory effect 
of ikarugamycin and quercetin are mainly due to A20 induction as the anti-inflammatory 
effect is lacking in bronchial epithelial cells with A20 knockdown.  
The effect of fluvastatin, which was predicted not to modify A20, was also confirmed. We 
have identified a process whereby already licensed drugs can be successfully repositioned for 
chronic inflammatory airway diseases. 
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Abstract 
Cystic Fibrosis (CF) lung disease is characterised by a chronic and exaggerated inflammation 
in the airways. Despite recent developments to therapeutically overcome the underlying 
functional defect in CFTR (cystic fibrosis transmembrane conductance regulator), there is 
still an unmet need to also normalise the inflammatory response. The prolonged and 
heightened inflammatory response in CF is in part mediated by a lack of intrinsic 
downregulation of the pro-inflammatory NF-kB pathway.  We have previously identified 
reduced expression of the NF-κB down-regulator A20 in CF as a key target to normalise the 
inflammatory response. Here we have used publically available gene array expression data 
together with sscMap (statistically significant connections’ map) to successfully predict drugs 
already licensed for the use in humans to induce A20 mRNA and protein expression and 
thereby reduce inflammation. The effect of the predicted drugs on A20 and NF-kB(p65) 
expression (mRNA) as well as pro-inflammatory cytokine release (IL-8) in the presence and 
absence of bacterial LPS was shown in bronchial epithelial cells lines (16HBE14o-, 
CFBE41o-) and in primary nasal epithelial cells (PNECs) from patients with CF (Phe508del 
homozygous) and non-CF controls. Additionally, the specificity of the drug action on A20 
was confirmed using cell lines with TNFAIP3 (A20) knockdown (siRNA). We also show that 
the A20 inducing effect of ikarugamycin and quercetin is lower in CF derived airway 
epithelial cells than in non-CF cells.  
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Introduction 
The response to pathogens, recognised by pattern recognition receptors including Toll-like 
receptors (TLRs), triggers an acute innate immune response that is mediated by transcription 
factors such as nuclear factor-kappa-light-chain enhancer of B cells (NF-κB). NF-κB activation 
promotes the transcription of inflammatory mediators in a tightly regulated process. However, in 
individuals with underlying chronic inflammatory diseases, this regulation is compromised, 
leading to constitutive NF-κB activation and persistent inflammation (1-3) 
The development of new first-in-class medicines is costly (approximately $1.2 billion 
for a single FDA-approved drug) and takes between 10 and 15 years (4, 5). Many newly 
developed drugs perform well in the preclinical testing, but fail when tested in humans (6). Thus 
alternative approaches using predictive models to identify new drugs are needed. Gene expression 
connectivity mapping (www.broadinstitute.org/cmap/) is an advanced bioinformatics technique to 
establish the connections among biological states via gene expression profiles/signatures. One 
major application of connectivity mapping is to identify potential small molecules able to inhibit a 
disease state or regulate the expression of a small number of genes (7-9). We used an advanced 
version of connectivity mapping, sscMap (statistically significant connections’ map) (10), 
which has been successfully applied to phenotypic targeting and predicting effective drugs in 
cancer (10). However, this has not yet been applied to chronic inflammatory diseases. 
Cystic Fibrosis (CF) is a chronic multi-organ inflammatory disease, caused by mutations 
in the CFTR gene (Cystic Fibrosis Transmembrane Conductance regulator) expressed on apical 
epithelial surfaces. It is the most common lethal genetic disease in Caucasian populations. Lung 
disease is the primary cause of morbidity and mortality in CF, resulting from dehydration of 
epithelial surfaces and reduced mucociliary clearance as a consequence of the ionic imbalance 
created by CFTR mutation. This leads to a cycle of infection and inflammation associated with a 
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progressive reduction in lung function and eventual respiratory failure. A common feature of CF is 
the heightened, chronic inflammatory response to Pseudomonas aeruginosa (P. aeruginosa), 
driven by constitutive NF-κB activation in airway and peripheral blood cells (2, 3, 11). Primary 
nasal epithelial cells (PNECs) from patients with the common F508del/F508del mutation and a 
milder genotype (R117H/F508del), show a significant increase in NF-κB(p65) which correlates 
with disease severity (12).  
A20 (TNFAIP3) is a central negative regulator of NF-κB activation following stimulation 
of TLRs and/or TNF-receptor and regulates different signalling pathways such as NF-kB and 
interferon regulatory factor (IRF) signalling (13). A20 modifies classical immune cells (14, 15) 
as well as epithelial cells (12), endothelial cells (16), embryonic fibroblasts (17), osteoclasts 
(18) and pancreatic beta-cells (19) and diverse roles for A20 in innate immunity, apoptosis, 
autophagy and antigen processing (13, 15, 16, 20). Within the innate inflammatory immune 
response A20 regulates NF-κB signalling at the level of TRAF6 in mouse embryonic fibroblasts 
(MEFs) and osteoclasts (17, 18). In cultured human airway epithelial cells, A20 is rapidly induced 
by viral or bacterial compounds (21) and is essential for termination of the TLR4 signal (22). 
PNECs stimulated with P. aeruginosa LPS show a transient increase in A20, but CF PNECs 
display lower A20 expression basally and after LPS stimulation (12, 23). 
Therefore, A20 induction should have anti-inflammatory effects within the tightly 
regulated NF-kB signalling pathway as shown by the induction of A20 through gibberellin (GA3) 
in airway epithelial cells. GA3 induced A20, reduced IL-8 secretion, stabilised cytosolic IkBα and 
reduced NF-κB (p65) activation (24). Here we set out to identify additional compounds able to 
induce A20. Thus, we performed a compound search using gene expression connectivity mapping 
to identify existing drugs that could induce A20 expression.  
 
Results 
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1. Connectivity mapping (sscMap):  
 
The selection of gene array data and creation of the gene signature 
 
Data sets that passed the selection criteria contained human primary nasal epithelial cells (PNECs) 
and the human bronchial epithelial cell lines CFBE41o-, Calu-3 and IB3-1 analysed basally and 
after exposure to P. aeruginosa LPS (Table 1). In total 76 samples from 4 different published 
gene array data sets were used. Linear expression correlation and GO enrichment analysis for 
NF-κB pathway genes identified the closest correlates to A20. Table 2 shows the top 7 genes that 
subsequently served as the input to the connectivity mapping process. 
 
Prediction of drugs to induce A20 in airway epithelial cells 
This study sought small molecular compounds that may enhance A20 expression and as a 
confirming negative control, those compounds that may inhibit A20 expression. Table 3 
summarizes the top candidate drugs identified. The column entitled ‘significance’ shows the 
significance of drugs based on p values and the column ‘z-score’ shows the correlation of the 
drugs with the input gene signature. Positive z-scores indicate a positive correlation i.e. the input 
genes are induced when treated with the particular drug. The significant drugs with the highest 
positive z-scores along with a negative control were selected for laboratory validation. In addition 
to p values and z scores, stability of the connections was measured by altering the gene signature 
and the significance of the connections are given under the column ‘perturbation stability’. Drugs 
with perturbation stability 1 represent strong connections which remain significant with 
‘perturbation’ gene signatures. From these predictions two A20 inducing drugs (ikarugamycin and 
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quercetin) as well as one non-A20 inducing drug (fluvastatin) were chosen for further 
investigation. 
 
2. Gene expression of gene signature 
Expression of the genes identified as the A20/NF-kB gene signature in CF epithelial cells 
were analysed by qRT-PCR in 16HBE14o- and CFBE41o- cultured in the presence or 
absence of LPS for 0-24h (Figure 1).  
Basal expression: CFBE41o- show significantly lower mRNA expression for A20, ATF3, 
Rab5c and ICAM1 compared to 16HBE14o- (all p<0.05, n=5). Expression of DENNDA4 
and PSNE1 was also lower in CFBE41o- but this did not reach significance. 
LPS induced expression: In 16HBE14o-, A20 mRNA is rapidly induced with expression 
peaking 1h after LPS exposure (p<0.001 compared to medium, n=5), while CFBE41o- show 
significantly lower (at 1h p<0.001 vs. 16HBE14o-, n=5) and delayed (maximal induction at 
4-8 h, p<0.01 and 0.001 vs. medium, n=5) induction upon LPS stimulation.  After LPS, 
ATF3 and ICAM1 expression was significantly lower in CFBE41o- compared to 16HBE14o- 
(p<0.01, n=5). Pom121 and PSNE1 expression increased in CFBE41o- compared to medium 
(8h, p<0.05 and p<0.01) and in CFBE41o- compared to 16HBE14o- (8h, p<0.05 and 
p<0.001). 16HBE14o- showed a significant reduction in DENNDA4 and Rab5c expression 
compared to medium (1h, p<0.05 and 4h, p<0.05, respectively), but there was no significant 
change in the expression of these genes in CFBE41o-.  
 
3. Effect of A20 inducing drugs on cell lines  
LDH release in drug exposed 16HBE14o- and CFBE41o-: LDH release was measured after 
exposure to the drugs alone (0.01–1000 µM) and with LPS stimulation (supplement Figure 1S). 
Quercetin did not cause any LDH release. Overall fluvastatin was almost without effect on LDH; 
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the exceptions were a slight but statistically significant increase at 10 µM alone (CFBE41o-) and 
in the presence of LPS (in CFBE41o- and 16HBE14o-). Ikarugamycin (1, 100 µM) caused a 
significantly higher LDH release in both cell types. In LPS stimulated cells, 0.1 μM ikarugamycin 
and higher concentrations showed a higher LDH release compared to LPS alone, but this did not 
reach statistical significance (supplement Figure 1S). 
 
LPS stimulated IL-8 release in drug pre-treated 16HBE14o- and CFBE41o-: To assess the anti-
inflammatory potential of the selected drugs, cells were pre-treated with the drug for 1h, stimulated 
with LPS and the IL-8 release measured and the relative IC50 calculated (supplement S3). In 
16HBE14o-, all drugs reduced IL-8 release by at least 50% with an IC50 of 15.6 μM for 
ikarugamycin, 0.09 μM for quercetin and 0.11 μM for fluvastatin. In CFBE41o-, only quercitin 
(IC50 0.03 μM) and fluvastatin (IC50 0.001 μM) pre-treatment were able to reduce release by 50%.  
In contrast, pre-treatment of CFBE41o-  with 1 μM ikarugamycin caused a significant increase in 
IL-8 release compared to LPS alone (LPS 269.9 ± 47.9 pg/ml vs. 590.7 ± 82.6 pg/ml, p<0.05, 
n=5). Therefore, a meaningful calculation of the relative IC50 for IL-8 release in ikarugamycin 
treated CFBE41o- cells was not possible.  
 
A20 mRNA induction in drug treated 16HBE14o- and CFBE41o-: To elucidate if ikarugamycin 
and quercetin facilitate their anti-inflammatory action though the induction of A20 as predicted, 
A20 mRNA was determined by qRT-PCR. Fluvastatin was included as a negative control. Using 
the LDH and IL-8 release data two drug concentrations were selected for further investigations 
(supplement S3).  In 16HBE14o-, LPS stimulation caused a significant induction of A20 1h after 
stimulation (Figure 2). Ikarugamycin (0.01 µM) alone did not cause a significant induction of 
A20, but additional LPS stimulation caused a significant A20 induction at 24h (p<0.05 vs LPS 
24h). 1 μM ikarugamycin significantly induced A20 at 4h on its own, but the higher A20 
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expression in the presence of LPS (1-24h) did not reach statistical significance. Quercetin pre-
treatment did not induce significant levels of A20 mRNA at 0.1 μM, alone or in the presence of 
LPS. However, at 100 μM quercetin A20 mRNA was significantly induced alone at 1h and 4h 
(p<0.05 vs. medium 1h and 4h) and in the presence of LPS at 4h (p<0.05 vs. LPS 4h). Fluvastatin 
alone did not induce A20 mRNA at any time or concentration (Figure 2), in the presence of LPS 
fluvastatin pre-treatment caused a significant reduction in A20 mRNA at both concentrations 
tested (p<0.001 for 0.1 μM+LPS 1h vs. LPS 1h; p<0.05 for 1 μM+LPS 1h vs. LPS 1h). In 
CFBE41o-, LPS significantly induced A20 at 4h (p<0.05), but induction levels were lower than in 
16HBE14o- (Figure 2). Ikarugamycin (1 µM) induced significant levels of A20 at 4h and 24h 
(both p<0.05), this was further increased in the presence of LPS at 4h (p<0.05 vs LPS 4h) and 24h 
(p<0.01 vs LPS 24h). Quercetin treatment alone significantly induced A20 at 4h at both 
concentrations (p<0.05 0.1 μM vs. medium 4h and p<0.01 100 μM vs. medium 4h). In the 
presence of LPS, only 100 μM quercetin caused a significant induction of A20 at 24h (p<0.05). 
Fluvastatin alone did not induce A20 mRNA at any time or concentration (Figure 2), and in the 
presence of LPS fluvastatin caused a significant reduction in A20 mRNA at both concentrations 
tested (p<0.05 for 0.1 μM+LPS 4h vs. LPS 4h; p<0.05 for 1 μM+LPS 4h vs. LPS 4h). 
 
Effect of selected components on NF-kB (p65) mRNA in 16HBE14o- and CFBE41o-: Next we 
investigated if A20 induction altered NF-κB(p65) mRNA levels (Figure 2). LPS stimulation 
caused a significant induction of p65 1h after stimulation in 16HBE14o- (p<0.01 – p<0.001 vs. 
medium). Ikarugamycin (0.01 µM) was without significant effect on p65 mRNA. At 1 μM, 
ikarugamycin alone induced p65 at 24h (p<0.01 vs. medium 24h) and in the presence of LPS at 1h 
and 4h (both p<0.05 vs. LPS). Quercetin alone showed no effect on p65 mRNA levels, but when 
stimulated with LPS both concentrations of quercetin (0.1, 100 μM) significantly reduced p65 
mRNA levels at 1h (p<0.01 vs LPS 1h). Similar to quercetin, fluvastatin alone showed no effect 
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on p65 mRNA levels, but after LPS stimulation fluvastatin (0.1, 100 μM) significantly reduced 
p65 mRNA levels at 1h (p<0.001 and p<0.05 vs LPS 1h). In CFBE41o- LPS significantly induced 
p65 at 1h, 4h and 24h (p<0.05-0.001 vs medium) and overall CFBE41o- exhibited higher 
expression levels of p65 at 4h and 24h than 16HBE14o- (Figure 2). Ikarugamycin was without 
significant effect on p65 mRNA expression at any concentration or time point, although overall 
expression levels appear higher at 1 μM, when stimulated with LPS (Figure 2). In CFBE41o-, 
quercetin (0.1 μM) did not affect p65 mRNA levels. At 100 μM, quercetin significantly induced 
p65 (p<0.05: quercetin alone 100 μM 24h vs. medium 24h and quercetin 100 μM + LPS 24h vs. 
LPS 24h). Fluvastatin caused a significant reduction in p65 mRNA at both concentrations and all 
time points after LPS stimulation (p<0.05 and p<0.01 for 0.1 μM+LPS vs. LPS; p<0.05 and 
p<0.01 for 1 μM+LPS vs. LPS) (Figure 2). 
 
Effect of predicted drugs on A20 and p65 protein expression: We then determined the effect of 
the drugs on cytosolic A20 and p65 protein by Western Blotting using the same selected 
concentrations than before. Ikarugamycin (0.01 µM) induced A20 protein in both 16HBE14o- and 
CFBE41o-, with less A20 protein induction at 1 μM. Ikarugamycin also induced cytosolic p65 in 
both cell types (Figure 3a). Quercetin treatment caused a strong induction of A20 protein at both 
concentrations (0. 1, 100 μM) in 16HBE14o- and to a lower degree in CFBE41o-. Quercetin (100 
µM) reduced cytosolic p65 in 16HBE14o- and in CFBE41o- (Figure 3b). Fluvastatin did not 
induce A20 protein at either concentration (0.1, 1 μM) in both 16HBE14o- and CFBE41o- cells. 
Fluvastatin pretreatment reduced cytosolic p65 protein in 16HBE14o- cells though this was only 
apparent at the higher concentration in CFBE41o- (Figure 3c). 
 
Specificity of the drug effect on A20 mRNA expression using A20 siRNA: To confirm that the 
effect of the selected drugs is facilitated through A20 induction, we used siRNA to knock down 
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A20 expression in 16HBE14o- cells as previously described (30). Cells were pre-treated with 
quercetin or ikarugamycin prior to LPS and IL-8 determined. Results (Figure 4) showed that in 
16HBE14o- LPS significantly induced IL-8 (p<0.05 compared to untreated control), but when 
A20 is knocked down IL-8 increased further (although not significantly different from LPS 
alone). When cells are pre-treated with quercetin (100 μM) or ikarugamycin (1 μM), the LPS 
induced IL-8 release was significantly reduced (p<0.05). However, when A20 is knocked 
down IL-8 levels were not different from LPS control (Figure 4). 
 
4. Effect of A20 inducing drugs on PNECs 
 
Effect on IL-8 release: LPS significantly induced IL-8 release from PNECs from non-CF and CF 
patients (non-CF: p<0.01, CF: p<0.05, Wilcoxon paired test, Figure 5). IL-8 release from CF 
PNECs was significantly higher than from non-CF PNECs (600.6±62.8 pg/ml vs. 315.8±36.1 
pg/ml, p<0.01, Mann-Whitney test). In non-CF PNECs (Figure 5a), pre-treatment with 
ikarugamycin at 0.01 μM, but not at 1 μM significantly reduced LPS induced IL-8 release 
(p<0.05). In quercetin and fluvastatin treated non-CF PNECs only the higher concentrations tested 
(quercetin: 100 μM and fluvastatin: 1 μM significantly reduced IL-8 release (p<0.01 and p<0.05, 
respectively, Figure 5a). PNECs from patients with CF showed similar results with a significant 
IL-8 reduction at the lower concentration of ikarugamycin (0.01 μM, p<0.01) and the higher 
concentration of quercetin (100 μM, p<0.05). In CF PNECs fluvastatin treatment significantly 
reduced IL-8 release at both concentrations tested (0.1 μM, p<0.05; 1 μM, p<0.01, Figure 5b). 
 
A20 induction in PNECs: In PNECs from non-CF control subjects (Figure 6) LPS stimulation 
resulted in a rapid and significant upregulation of A20 mRNA within 1h and a peak expression at 
4h (p<0.05, LPS  vs. medium at 1h and 4h). Ikarugamycin alone at 0.01 μM increased A20 
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mRNA which reached significance at 24h (p<0.01) and in the presence of LPS this increase was 
significantly higher at 1h and 24h than LPS alone (p<0.05 and p<0.01 vs. LPS). Ikarugamycin (1 
μM) had no effect on A20 mRNA induction, either alone or in the presence of LPS. Quercetin (0.1 
μM) caused a significant induction of A20 compared to medium control at 1h, 4h and 24h (all 
p<0.01) with expression levels similar to those induced by LPS (Figure 6) and this was 
maintained the presence of LPS, with a peak A20 induction at 4h. The higher concentration of 
quercetin (100 μM) significantly induced A20 mRNA at 1h (p<0.05) and subsequent stimulation 
with LPS resulted in significantly increased A20 mRNA levels at 4h (p<0.05 vs LPS 4h). 
Fluvastatin treatment did not induce A20 mRNA expression, but 1μM reduced A20 mRNA at 4h 
LPS (Figure 6).  
In CF PNECs LPS induced A20 mRNA expression was lower than in non-CF PNECs, but 
in CF PNECs LPS induced significant levels of A20 mRNA 4h after LPS (p<0.05 vs. medium 
4h). Ikarugamycin at 0.01 μM (alone and in the presence of LPS) had no effect on A20 mRNA 
levels (Figure 6) but 1 μM ikarugamycin significantly induced A20 mRNA at 4 and 24h alone 
(p<0.05 vs medium control) and in the presence of LPS (p<0.05 and p<0.001 vs LPS).  Similarly, 
quercetin treatment with the lower concentration (0.01 μM) alone and in the presence of LPS had 
no effect on A20 mRNA levels (Figure 6), while 100 μM quercetin significantly induced A20 
mRNA alone (4h, p<0.05 vs medium control) and additionally above LPS induction (1h and 24h, 
both p<0.05 vs LPS). Similar to non-CF PNECs, fluvastatin treatment of CF PNECs had no 
significant effect on A20 mRNA expression levels. 
 
NF-κB (p65) induction in PNECs:  PNECs from non-CF control subjects respond to LPS 
exposure with a significant increase in NF-κB (p65) at 1h and 4h (p<0.001 vs medium control). 
Thereafter, p65 mRNA expression returns to its corresponding medium control value (Figure 6). 
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PNECs from patients with CF however show the expected high levels of p65 throughout the 24h 
studied (p<0.01 at 1h, p<0.05 at 4h and 24h vs medium control) (Figure 6).   
In non-CF PNECs, ikarugamycin treatment alone did not change p65 mRNA levels (vs 
medium control), but in the presence of LPS p65 mRNA was significantly reduced (p<0.05 at 1h, 
p<0.01 at 4h vs LPS). Overall the higher concentration of ikarugamycin induced p65 mRNA 
levels with a significant increase at 4h (p<0.05 vs medium control). However, in the presence of 
LPS, p65 levels remained not significantly different from those after LPS exposure at 1h and 24h, 
but were significantly lower compared to LPS alone at 4h (p<0.05) (Figure 6). The lower 
concentration of 0.01 μM quercetin alone did not modify basal p65 mRNA. After subsequent LPS 
challenge p65 mRNA significantly decreased at 1h (p<0.01 vs LPS), but then increased in a 
similar manner to LPS alone. However, 100 μM quercetin alone significantly reduced p65 
induction at 1h and 4h (p<0.05 and p0.01 vs. medium control). In the presence of LPS this 
reduction of p65 mRNA reached statistical significance at 4h and 24h (both p<0.05 vs LPS) 
(Figure 6). Fluvastatin (0.1 μM) induced p65 at 4h (p<0.05 vs. medium 4h), but p65 levels remain 
significantly lower when LPS is added (p<0.05, vs LPS at 1h and 4h). The higher concentration of 
fluvastatin (1 μM) did not change p65 levels alone, but after addition of LPS, p65 mRNA was 
initially reduced (1h p<0.05 vs LPS) but then induced similarly to LPS alone (Figure 6). 
 When PNECs from patients with CF were pre-treated with ikarugamycin, p65 levels dropped 
significantly at 0.01 μM ikarugamycin in the absence or presence of LPS (p<0.05-0.01). At the 
higher concentration of 1 μM p65 levels appeared lower, but this only reached statistical 
significance at 1h (p<0.05 vs LPS) (Figure 6). Pre-treatment of CF PNECs with quercetin did not 
affect p65 levels alone at either concentration tested, but at 0.1 μM quercetin in the presence of 
LPS significantly reduced p65 at 24h (p<0.05 vs LPS). Treatment with 100 μM quercetin 
significantly reduced p65 mRNA in the presence of LPS at all time points (all p<0.05 vs LPS) 
(Figure 6). Fluvastatin alone had no significant effect on p65 mRNA levels, but significantly 
14 
 
reduced LPS induced p65 at 1h, 4h and 24h (p<0.05 vs. medium 1h, 4h or 24h), while the higher 
concentration of fluvastatin (1 μM) showed no significant effect on basal or LPS induced p65 
mRNA (Figure 6). 
 
Discussion  
Airways infection and the subsequent inflammation are deleterious for patients suffering from CF. 
Current drugs targeting the mutated CFTR (potentiators/correctors) improve expression and 
function of CFTR on epithelial surfaces and patients showed improved lung function and 
reduced frequency of pulmonary exacerbations, hospitalization and use of intravenous 
antibiotics, bu augmented CFTR function failed to reduce inflammatory markers in sputum 
(e.g. IL-1,-6,-8) (25) and heterogeneous responses to the treatment have been reported (26), 
suggesting that CFTR correction/potentiation may not directly improve the underlying 
compromised immune response. The negative NF-κB regulator A20 (TNFAIP3) is reduced in 
CF airway epithelial cells, basally and after LPS stimulation (23) and is associated with 
markers of inflammation and decreased lung function (12). A20 silencing increased TRAF6 
and NF-κB activity (18), and A20 over-expression had protective effects in airway 
inflammation in ‘asthmatic mice’ (27), suggesting that A20 augmentation normalises the 
inflammatory response in the airways.  
In order to find agents to induce A20 in CF we employed sscMAP, which has been 
widely used in drug development uncovering potential new indications for existing drugs as 
well as predicting side effects (28). Using disease specific publicly available gene array data 
(GEO data sets), we used connectivity mapping to firstly identify the target gene (A20) related 
gene signature and to secondly predict already licensed drugs to induce A20 expression. We 
included a total of 76 gene array data from primary nasal epithelial cells and cell lines commonly 
used in CF research (Table 1). Gene array databases were first selected in August 2013, but a 
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recent (Jan 2016) search revealed no further significant published gene array data on CF 
(primary nasal) epithelial cells. 
 The applied linear regression model (Pearson’s correlation coefficient) is an 
established robust method to identify the correlates of a known gene expression estimating 
the strength of a linear relationship between two random normally distributed variables (29). 
The application of the linear regression model with GO (gene ontology) selection revealed a gene 
signature of 6 genes additionally to the seed gene A20 (Table 2) and we confirmed that the 
expression of these genes is similarly reduced in CF epithelial cells, basally and after LPS 
stimulation (Figure 1). The identified A20 correlates were ATF3, a transcriptional repressor that 
binds to cAMP response elements (CRE); RAB5C, a small ubiquitously expressed GTPase; 
DENND4A, which encodes the C-Myc Promoter Binding Protein (MBP-1); POM121, a 
nuclear transmembrane protein and essential component of the nuclear pore complex; ICAM1, 
a cell surface glycoprotein typically expressed on endothelial and immune cells, especially 
during inflammation and PSEN 1 (Presenilin 1), a catalytic component of γ-secretase and a 
DREAM binding protein. Further descriptions of these genes and their involvements in 
inflammation can be found in the online appendix. These genes, as a combined gene 
signature, were then input into the sscMAP process comparing the gene expression of the 
gene signature with the gene expression in the reference database (www.broadinstitute.org), 
which was obtained from systematic microarray gene expression profiling.  
SscMAP predicted a short list of drugs that should modify the expression profile of 
the gene signature genes, including A20. Those drugs included azacyclonol, ikarugamycin, 
quercetin and karakoline (Table 3). Azacyclonol is a drug used in psychotic individuals (30). 
We excluded azacyclonol, as its use requires special permission through relevant government 
authorities. Interestingly, the anti-histamine terfenadine is metabolised to azacyclonol and 
terfenadine (31). Karakoline is a highly toxic plant diterpenoid (32) and the pharmacological 
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effects of preparations of Aconitum roots are attributed to diterpenoid alkaloids (33). The 
anti-inflammatory activity of gibberellin (GA3), also a plant-derived diterpenoid, is mediated 
through A20 induction (24). We therefore selected ikarugamycin and quercetin for further 
studies. 
Ikarugamycin is a macrolide antibiotic with cytostatic effects against Gram-positive 
bacteria. We show that ikarugamycin exhibits anti-inflammatory properties in LPS stimulated 
airway cells. In 16HBE14o- ikarugamycin showed a dose-dependent reduction of LPS-
induced IL-8 release (supplement S4), through induction of A20 and reduction of p65 
(Figure 2). 16HBE14o- and CFBE41o- did not show reduced cell viability at concentrations 
lower than 1 μM, higher concentrations increased LDH release suggesting a cytotoxic effect 
(supplement S2). CFBE41o- appear more sensitive to ikarugamycin treatment (supplement 
S4), which made it not possible to calculate a meaningful relative IC50 value (supplement S3), 
although p65 protein expression was not increased (Figure 2). In HL-60 cells, ikarugamycin 
reduced cell viability and increased DNA fragmentation starting at 0.1 µM (IC50 of 0.22 μM), 
while MCF-7 cells and peripheral blood mononuclear cells showed higher resistance. 
Furthermore, ikarugamycin treatment of HL-60 cells caused a significant caspase activation, 
increase in intracellular calcium and p38 MAP kinase activation (34). However, investigating 
the pro-apoptotic mechanisms in bronchial epithelial cells was beyond the scope of this study. 
Nonetheless, our ikarugamycin data at near cytotoxic levels add valuable information:  
Firstly, sscMap correctly predicted that ikarugamycin would induce A20 mRNA but sscMap 
does not predict the physiological effect of the gene induction. CF cells overall show a 
limited ability to induce A20, however, our results show that – given the right stimulus – CF 
cells are indeed able to induce A20 mRNA and the high induction of A20 at near cytotoxic 
levels may be able to counteract the pro-apoptotic stimulation of ikarugamycin. 
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Quercetin, a flavonoid, is known for its anti-inflammatory effects. In vivo studies 
have shown antioxidant, anti-inflammatory, anti-tumour and even anti-infectious properties 
of quercetin, which are promoted through its effects on signalling pathways such as NF-κB 
(35). In lung epithelial cells, quercetin inhibited IL-1 and TNF-α induced IκBα degradation 
and NF-κB activity through modification of the MAPK pathway (AP-1) (36). SscMap 
correctly predicted that quercetin can induce A20 mRNA, adding a new mechanism for the 
anti-inflammatory effects of quercetin.  It also significantly reduced LPS-induced IL-8 
release in both cell types with a relative IC50 of 0.15 and 0.04 μM in 16HBE14o- and 
CFBE41o-, respectively. Quercetin at concentrations up to 1000 μM did not show any 
cytotoxicity, although in neuronal cell cultures quercetin higher than 100 μM was cytotoxic 
(37). Within the in vivo antioxidant network, quercetin has been described to be oxidised and 
to yield an ortho-quinone, which, in absence of reducing glutathione, can oxidise protein 
thiols impairing enzyme activities (38). We have not investigated the antioxidant status of our 
cell culture, but we took precautions to minimise oxidation when preparing our quercetin 
dilutions. 
To further investigate the A20-dependent mechanism of the anti-inflammatory action 
of quercetin and ikarugamycin, we used A20 knock down in 16HBE14o-. As previously 
described for the A20 inducing anti-inflammatory compound gibberellin (24), we were able 
to confirm that the anti-inflammatory effect of the predicted drugs was indeed mainly 
mediated by the induction of A20. 
We also tested fluvastatin, which was predicted not to affect or reduce A20 gene 
expression (negative z-score). Although fluvastatin exerted anti-inflammatory effects (IL-8) 
in both cell lines, our data show that this was not mediated by the induction of A20 (mRNA), 
clearly confirming the sscMap prediction. In asthma, fluvastatin inhibits eosinophil adhesion 
to ICAM-1 (39) and fibroblast proliferation (40). Using similar concentrations we did not 
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observe any reduced proliferation.  Fluvastatin at a concentration range similar to those we 
used, reduced basal and LPS-induced IL-8 release from LPS stimulated whole blood cells, 
with CF cells appearing more sensitive to fluvastatin than control cells (IC50: 19.1 μM in non-
CF cells, 4.6 μM in CF blood cells) (41). In isolated LPS-stimulated peripheral blood 
monocytes from patients with chronic kidney disease fluvastatin had a significant anti-
inflammatory effect (IL-8, IL-6) at a concentration range of 0.0001–1 μM (42). Patients with 
heart transplants receiving 40 mg fluvastatin/day for 4 weeks showed a significant reduction 
in total cholesterol levels and a maximum blood fluvastatin concentration of 2.11 and 3.77 
μM. These studies suggest that we have covered a physiologically relevant range of 
fluvastatin. However, fluvastatin metabolism may be affected by concomitant therapies, 
especially substances competing with cytochrome enzymes and in such cases fluvastatin 
levels may need to be monitored (43).  Any reactions with other therapies (as they would 
appear in patients with CF) were not investigated in our manuscript as they would have been 
beyond the scope of the study. 
Similar to ikarigamycin, fluvastatin has been described to have pro-apoptotic effects 
e.g. in human lymphoma cells, human smooth muscle cells and in rat neonatal cardiac 
myocytes or rat vascular smooth muscle cells (44, 45), mediated through activation of 
caspase-3, reactive oxygen species and activation of p38 MAPK (44, 55). However, statins, 
through their inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), but not through 
induction of A20, may still have therapeutic potential in airway and systemic inflammation in 
CF (41).  
Overall, our study shows that connectivity mapping (sscMap) can predict A20 
inducing drugs. Pre-treatment of cells with both ikarugamycin and quercetin reduces LPS-
induced IL-8 secretion by induction of A20. In non-CF PNECs both drugs upregulated A20 
and reduced IL-8 and p65 mRNA at lower concentrations than in cell lines. CF PNECs, 
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however, have a reduced and delayed A20 inducing response to LPS and to the tested drugs 
and a significant A20 induction appears at the higher concentration of the drugs tested, which 
might be near to the cytotoxic effect. A20 reduces apoptosis (46, 47) and mutational loss of 
A20 resulted in rapid apoptosis and inflammation in hematopoietic cells (48). We did not 
determine markers of apoptosis in our study, but the huge increase in A20 mRNA may 
indicate a possible counteraction to pro-apoptotic changes in response to ikarugamycin 
treatment. Of particular interest, this may indicate a higher susceptibility/sensitivity of CF 
cells to pro-apoptotic stimuli. 
Our study has several limitations. Firstly, for the sscMAP process a huge number of 
gene array samples are required and although the database search gave a high number of initial 
results, upon detailed inspection several gene array studies could not be included. Connectivity 
mapping uses gene array data run on Affimetrix platforms and we selected those performed 
on these platforms. Several published gene array studies were performed in cell lines. However, 
the majority of samples selected were PNECs (n=40), but we also included data from cell 
lines. Furthermore, every published dataset has been performed using a specific experimental 
design with respect to treatments and time points. We selected experiments that used either no 
stimulation or exposure to P.aeruginosa LPS or to P.aeruginosa itself. A sample size of 50-
100 individual samples is a statistically acceptable sample size to produce an unbiased result 
and we used 76 individual gene array samples.  
Secondly, the reference database was generated using different cell lines: MCF7, HL60, 
PC3 and SKMEL5. Although all of human origin, none of these cell lines are airway derived. We 
therefore confirmed the effect of the predicted drugs in airway relevant and disease specific cell 
lines, determined an effective drug concentration in our disease model and confirmed their effect 
in primary cells. Additionally, factors such as the interaction between various signalling pathways 
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and the interplay between genes can affect the functions of the predicted and validated drugs when 
used in humans.  
The aim of our study was to investigate the potential of sscMap to predict A20-
inducing drugs from a list of drugs already licenced for the use in humans to make them 
available for drug repositioning. As a proof of concept we have focused on the LPS induced 
expression of A20, p65 and cytokines IL-6 and IL-8. However, in addition to its direct 
regulation of TLR-induced NF-κB activation, A20 is also involved in the negative regulation 
of the of NLRP3 inflammasome via TLR3/4-(TRIF)-RIPK3 (49) may also inhibit 
inflammation induced regulated necrosis (necroptosis) via RIPK3 (50), adding further levels 
of action and complexity to the anti-inflammatory action of A20. Therefore, future work 
analysing further NF-κB driven cytokines such as TNFα and IL-1β would also indicate if the 
predicted drugs are able to modify A20 action on the inflammasome. 
 
Summary 
To date there is still a need for alternative anti-inflammatory drugs for patients with CF as 
restoring CFTR function with potentiators and correctors does not directly affect the inherent 
innate immune defect. The exaggerated inflammatory response is in part due to the lack of 
the NF-κB regulator A20 and pharmacological induction of A20 is anti-inflammatory.  We 
have shown here that sscMap is a potent tool to predict effective drugs that can modify A20 
without totally inhibiting NF-κB. This is particularly important in the clinical setting as 
pharmacological suppression of inflammation may increase the incidence of infective 
exacerbations (51). In addition, A20 inducing drugs have to be carefully adjusted as in 
addition to the A20 induction e.g. ikarugamycin can be pro-apoptotic.   A20 inhibits TNF-
induced pro-apoptotic signalling by inhibiting both, the activation of caspase 8 and the 
activation of c-Jun (52). However, neither the drug induced pro-apoptotic mechanisms nor 
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the A20 induced anti-apoptotic mechanisms have been investigated in this study, but our 
observation of cytotoxicity despite high anti-apoptotic A20 mRNA levels may suggest an 
overriding mechanism. Therefore, while sscMap successfully predicts drugs to modify A20, 
the effect of the candidate drugs must to be confirmed in a suitable model system to optimise 
treatments. 
Our study also suggests that pharmacological induction of A20 may be less efficient 
in CF airway cells, but given the appropriate stimulation, A20 induction is indeed possible. 
Tiruppathi et al. recently showed that A20 induction may be regulated not only via NF-κB, 
but also through the opposing effects of the repressor DREAM and transcription factor USF1 
(53). Future work will investigate if modifying the balance between A20 repressor and 
transcription factor in CF can more efficiently re-establish A20 induction.  
 
  
22 
 
Materials and Methods 
 
Selection of Gene Array data 
A search of PubMed GEO data sets (http://www.ncbi.nlm.nih.gov/gds/) was performed in August 
2013 using the search terms “Cystic Fibrosis”, “epithelial cells”, “airways” and “primary cells”.  
Data sets that passed the search criteria and were compatible to Affymetrix Human Genome 
U133A Array were selected.  
 
Connectivity Mapping (sscMap) 
Gene expression profiles were generated using Affimetrix Gene chip Microarray and the 
relative expression of treatment vs. control was sorted in descending order giving rise to 
~22000 rank ordered genes and their expression. 
 
Determination of the gene signature 
A gene signature (a set of genes that behaves in the same way or uniquely under a biological 
state) was created. A20 (TNFAIP3) was used as the known seed gene and a linear regression 
model was applied to create the gene signature from all selected GEO data. A20 correlates 
were identified by calculating the Pearson correlation coefficient between the expression of 
A20 and other genes using the formula (where x ̄ and y ̄ are the sample means of the two 
arrays of values and r was calculated in Excel: 
 
The correlation coefficient r demonstrates the association between A20 and other genes, 
either in a positive or negative direction. The significance of the observed correlations was 
measured by calculating the corresponding p values and applying a stringent p value 
threshold 1/N where N is the number of genes analysed. The significant r values were 
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selected as correlates of A20. Gene ontology (GO) enrichment analysis 
(http://geneontology.org/) was then applied to further filter the A20 correlates identifying 
those related to NF-κB. The subsequent gene signature (including A20) was used as the input 
query to evaluate the connection between them and the reference profiles (GEO, Accession 
Number GSE5258) (8). Based on the principles of Lamb’s connectivity mapping, we used a 
simpler and more robust method (9, 10), called sscMap (statistically significant connections' 
map), to determine the connections between the gene signature and the reference profile. The 
similarity between the gene signature and each gene expression reference profile was 
assessed via a connection score. Connection scores are a function of expression profile and 
the query gene signature, which is expected to reflect the underlying connection between 
them. The sscMap applies a robust and improved scoring system based on the following 
formulae:  
 
 
(Where gi represents the i th gene in the signature, s(gi) is its signed rank in the signature, and 
R(gi) is this gene's signed rank in the reference profile). To calculate the p value, after 
calculating the connection strength between a gene signature and the reference profile a large 
number of random gene signatures are created and the same number of connection scores are 
calculated and the proportion of scores higher than the observed score in absolute values is 
the p value. In addition to controlling false positives, sscMap is extended to measure the 
stability of the connections discovered by gene signature perturbation. In order to implement 
this, one gene is left out from the gene signature to derive ‘perturbation’ gene signature and 
the changes in the significant connections were observed. The connections which stay stable 
over the changes were given the perturbation stability score, defined as the fraction of times a 
drug remained significant under the perturbation process (54). 
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Cell Culture 
The bronchial epithelial cell lines 16HBE14o- (control) and CFBE41o- (CF, 
F508del/F508del), obtained from D. Gruenert, UCSF, USA were cultured as described (32). 
Primary nasal epithelial cells (PNECs) from CF patients (all F508del/F508del, n=5) and 
healthy volunteers (n=5, informed consent given, research ethics approval 07/NIR02/23) 
were cultured as previously described (55). Control participants did not have any acute 
airways disease at the time of sampling, or a history of any chronic airways inflammation.  
 
Cell culture stimulations 
Cells were exposed to the selected drugs (ikarugamycin, quercetin, fluvastatin (all Sigma-
Aldrich, SML0188, Q0125, SML0038, 0.01–1000 µM) at 0-1000 μM for 1 h prior to LPS 
stimulation (P. aeruginosa LPS, Sigma-Aldrich, L9143, 10 µg/mL, up to 24h). Stock 
solutions of the drugs were kept at -20°C for up to 3 months. To minimise oxidation or 
degradation of the compounds, the working dilutions were freshly prepared. 
 
Determination of LPS induced cytokine release (IL-6 and IL-8) 
IL-6 and IL-8 in cell-free culture supernatants were measured by a commercially available 
ELISA (PeproTech EC Ltd.) according to the manufacturer’s instructions.  
 
LDH Cytotoxicity assay 
Lactate dehydrogenase (LDH) release into cell culture supernatants was determined using a 
LDH-Cytotoxicity Assay Kit (BioVision Ltd.) according to the manufacturer’s instructions.  
 
Real time qPCR 
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Total RNA was extracted (GenElute™, RTN350, Sigma-Aldrich) and quantified. Equal 
amounts of RNA (250 ng) were reverse transcribed into cDNA (High-Capacity cDNA 
Reverse Transcription Kit, Applied Biosystems™) and quantitative RT-PCR performed 
(LightCycler thermal cycler system, Roche). Expression of A20, p65 and β-actin were 
assessed using primer sequences previously described (23) and given in supplement table S1. 
Relative expression to β-actin was calculated as ΔΔCt.  Jurkat cell cDNA acted as an internal 
calibrator for all experiments and was used to determine differences in basal gene expression. 
 
Western Blotting 
Cytosolic protein expression was determined by Western Blotting after extraction in RIPA 
buffer containing protease inhibitors (cOmplete™, Mini, Roche). Lysates were separated by 
SDS-PAGE and PVDF membranes incubated with 1 µg/ml primary antibody: A20 (ab74037, 
Abcam); p65 (C-20, Santa Cruz Biotechnology), washed, incubated with appropriate 
horseradish peroxidase-conjugated antibody and visualized on a BioRadChemi Doc XRS 
system (BioRad). Anti-GAPDH-HRP (ab-9484, Abcam) was used as a loading control. 
 
Transfections 
16HBE140- were seeded at 4x104 cells/well and allowed to attach overnight. Custom 
FlexiTube siRNA (QIAGEN, UK) was designed against TNFAIP3 and both cell lines 
transfected with 50 nM siRNA and Lipofectamine Transfection Reagent (Invitrogen, UK) 
over 72h. All experiments included mock transfection and scrambled controls. Gene silencing 
was assessed by qPCR as described above with knockdown of 74% ± 7.2; n=5) achieved. 
 
Statistical analysis  
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All data are presented as the means ± SEM. Differences between groups were analysed using 
the Kruskal-Wallis non-parametric ANOVA with Dunn’s post-test (*p<0.05, **p<0.01 and 
***p<0.001). $ denotes a significant difference compared to medium control, while * denotes 
significant differences between groups (CF vs. non-CF, comparing the same time points or 
LPS vs. treatment + LPS). The logarithmic inhibitor concentration versus the relative IL-8 
response achieving a 50% inhibition was calculated as the relative IC50. GraphPad Prism (La 
Jolla, California) was used to plot graphs and to analyse the data. 
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Legends: 
 
Figure 1: Gene expression profile of the gene signature genes associated with A20. 
16HBE14o- (grey) and CFBE41o- (green) were stimulated (LPS, 10 μg/ml 0-24 h) and 
mRNA levels of A20, ATF3, Rab5c, DENNDA4, POM121, ICAM-1 and PSNE1 determined 
as described. $ significant difference compared to medium control, * significant differences 
between genotypes. 
 
Figure 2: A20 and p65 mRNA expression of ikarugamycin, quercetin and fluvastatin 
treated cells. 16HBE14o- and CFBE41o- were pre-incubated with (a) ikarugamycin, (0.01, 1 
μM), (b) quercetin (0.1, 100 μM) or (c) fluvastatin (0.1, 1 μM) stimulated (LPS, 10 μg/ml, 0-
24 h), A20 mRNA determined (qRT-PCR) and expressed as A20/β-actin relative to the 
internal control. 
 
Figure 3: Effect of ikarugamycin, quercetin and fluvastatin on A20 and p65 protein 
expression. 16HBE14o- and CFBE41o- were pre-incubated with (a) ikarugamycin, (0.01, 1 
μM), (b) quercetin (0.1, 100 μM) or (c) fluvastatin (0.1, 1 μM) and stimulated (LPS, 10 
μg/ml, 0-24 h). Cytosolic A20 and p65 protein was determined by Western Blotting: 1 = Ctr, 
2 = LPS, 3 = drug at lower conc., 4 = drug at lower conc. + LPS, 5 = drug at higher conc., 6 = 
drug at higher conc., + LPS. 
 
Figure 4: The anti-inflammatory effect of ikarugamycin and quercetin is mediated by A20 
induction. 16HBE14o- with and without knock-down of A20 were pre-incubated with 
ikarugamycin, (1 μM) or quercetin (100 μM), stimulated and IL-8 analysed. Drug treatment 
caused a significant reduction in IL-8 (p<0.05) compared to LPS stimulation alone. A20 
knock-down resulted in a lack of the anti-inflammatory effect of the drug tested. 
 
Figure 5: Effect of ikarugamycin, quercetin and fluvastatin on IL-8 release from PNECs 
from (a) healthy controls and (b) patients with CF. The release of IL-8 (pg/ml) was 
determined using a commercially available IL-8 ELISA kit. Statistical analysis was 
performed using Wilcoxon paired ranked t-test. 
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Figure 6: Effect of ikarugamycin, quercetin and fluvastatin on A20 and p65 mRNA 
expression in PNECs from (a) healthy controls and (b) patients with CF. Cells were pre-
incubated with ikarugamycin, quercetin or fluvastatin at the indicated concentrations (0.01 – 
100 μM) and then stimulated (LPS, 10 μg/ml, 0- 24 h). A20 mRNA was determined by qRT-
PCR and expressed as A20/β-actin relative to internal control. 
 
Table 1: Selected GEO gene expression data sets selected for the connectivity mapping 
process. 
 
Table 2: Gene expression profile of NF-kB/A20 related genes in CF airway disease. Genes 
behaving in a similar way than the target gene A20 were determined using linear correlation 
analyses of the selected gene expression data sets. 
 
Table 3: Candidate compounds predicted to induce or reduce A20 expression. 
 
 
